Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088736 | 1.00 | TRPA1 (0.36) | TRPA1TRPM8 | |
| SCHEMBL8183428 | 1.00 | TRPA1 (0.36) | TRPA1TRPM8 | |
| SCHEMBL3269762 | 0.84 | TRPA1 (0.37) | TRPA1TRPM8 | |
| SCHEMBL584356 | 0.84 | TRPA1 (0.37) | TRPA1TRPM8 | |
| SCHEMBL5926940 | 0.84 | TRPA1 (0.37) | TRPA1TRPM8 | |
| SCHEMBL6907615 | 0.84 | TRPA1 (0.37) | TRPA1TRPM8 | |
| SCHEMBL27824250 | 0.82 | TRPA1 (0.36) | TRPA1TRPM8 | |
| SCHEMBL27488960 | 0.81 | TRPA1 (0.35) | TRPA1TRPM8 | |
| SCHEMBL28317324 | 0.81 | TRPA1 (0.35) | TRPA1TRPM8 | |
| SCHEMBL4733415 | 0.81 | TRPA1 (0.35) | TRPA1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132689-A1 | Complexing using an ortho carboxy acetal; biodrug delivery | ROCHE MADISON INC | 2008-06-05 | — | — | US | disclosed |
| US-7348453-B2 | Labile linkage for compound delivery to a cell | MIRUS BIO CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2005026253-A2 | LABILE LINKAGE FOR COMPOUND DELIVERY TO A CELL | MIRUS BIO CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054604-A1 | Labile linkage for compound delivery to a cell | ROCHE MADISON INC. | 2005-03-10 | — | — | US | disclosed |
| US-6162932-A | Stereoselective synthesis of endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054604-A1 | Labile linkage for compound delivery to a cell | AADAC, PAICS, FURIN | TRPA1 3803/4885TRPM8 3152/4885 |
| US-20080132689-A1 | Complexing using an ortho carboxy acetal; biodrug delivery | CEL, PAICS, OGA | TRPA1 4058/4885TRPM8 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.